33 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18.
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
H.C. Wainwright said that Altimmune Inc (NASDAQ: ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients.
See Why Altimmune Stock Plunged After Obesity Trial Data
Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist.
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer’s Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 27)
USPTO Site Shows Altimmune Application For Patent ‘Coronavirus Immunogenic Compositions And Uses Thereof’
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=6929&p=139&f=G&l=50&d=PG01&S1=20210826.PD.&OS=PD/20210826&RS=PD/20210826
Altimmune Sponsored Study ALT-801 In Diabetic And Non-Diabetic Overweight And Obese Subjects With Non-alcoholic Fatty Liver Disease Posted To clinical Trials Website Not Yet Recruiting
https://benzinga.slack.com/archives/G30T1LFMW/p1629127523156600
Understanding Altimmune’s Unusual Options Activity
Altimmune (NASDAQ:ALT) shares experienced unusual options activity on Wednesday. The stock price moved down to $10.8 following the option alert.
The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 10)